Atrium Therapeutics, Inc. 8-K

What Happened
Atrium Therapeutics, Inc. announced it completed the previously disclosed separation (spin‑off) from Avidity Biosciences, Inc., with the distribution of Atrium common stock effective February 26, 2026. Following the Distribution, Atrium became an independent, publicly traded company and began trading on the Nasdaq Global Select Market under the symbol “RNA” on February 27, 2026. The spin‑off transferred Avidity’s early‑stage precision cardiology programs (including ATR‑1086 and ATR‑1072) and certain collaboration agreements (notably with Bristol‑Myers Squibb Company and Eli Lilly and Company) to Atrium.

Key Details

• Distribution ratio: 1 share of Atrium common stock for every 10 shares of Avidity common stock. Distribution effective February 26, 2026.
• Nasdaq listing: Atrium commenced trading under ticker “RNA” on February 27, 2026.
• Control change: Immediately prior to the Distribution Avidity was Atrium’s sole stockholder; after the Distribution Avidity retains no ownership interest in Atrium.
• Corporate governance and agreements: On February 26, 2026 Atrium elected four directors (Carsten Boess, W. Michael Flanagan, Simona Skerjanec, Troy Wilson) with class terms specified; Atrium entered an Amended and Restated License Agreement with Avidity and a Transition Services Agreement, and filed employment agreements for Kathleen Gallagher and Brendan Winslow.

Why It Matters
The filing documents that Atrium is now an independent public company with its own board, management employment arrangements, and contractual relationships with its former parent (including IP license terms and transition services). For investors, this creates a standalone equity with public trading liquidity (ticker RNA) and places Atrium’s early cardiology programs and related collaborations under a separate corporate and governance structure. The Amended and Restated License Agreement and Transition Services Agreement define how Atrium and Avidity will share intellectual property and operational support post‑separation—items investors should review because they affect Atrium’s assets, rights and near‑term operations.